Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE SBS 6: Glepaglutide in Short Bowel Syndrome
NCT07228403Phase 3Active, not recruiting
- Sponsor
- Zealand Pharma
- Start
- Dec 2025
- Primary completion
- Sep 2028
- Countries
- 7
01
Overview
A Phase 3 trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Started Dec 2025; status: active, not recruiting.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT07228403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228403.